Abstract
In press
Background. Blastocystis is one of the most common intestinal protists in humans; its clinical significance is controversial, and no generally accepted eradication strategy exists. Infection outcomes are thought to depend on parasite subtypes, gut microbiota, and host immunity.
Aim. To determine the prognostic value of immunological parameters for the efficacy of therapy in patients with blastocystosis and to develop a prognostic algorithm on this basis.
Materials and Methods. Pre-treatment immunological parameters of 300 patients with blastocystosis aged 15–54 years who received complex therapy were analyzed retrospectively. Based on the regression of clinical symptoms one month after the start of treatment, patients were divided into Group A with a good therapeutic effect (regression ≥31%; n=162) and Group B with an insufficient effect (≤30%; n=138). Prognostic coefficients for parameter gradations and informativeness (J) were calculated using the heterogeneous sequential Wald–Genkin procedure; the prognostic threshold at the 95% reliability level was ±13. The study was conducted using SPSS Statistics 29 (IBM, USA) within the author's dissertation (implementation period 2021–2026).
Research Ethics. The study was conducted in accordance with the World Medical Association Declaration of Helsinki (1964–2024). All patients (for minors, their parents or legal representatives) signed informed consent to participate in the study. The research design was approved by the Ethics and Bioethics Commission of Kharkiv National Medical University (Protocol No.5 of May 05, 2021).
Results. High prognostic informativeness was found for the levels of immunoglobulin G (IgG; J=3.50), immunoglobulin A (IgA; J=2.53) and immunoglobulin M (IgM; J=2.12) and the proportion of CD8+ lymphocytes (J=1.50); moderate – for active T lymphocytes (J=0.87), CD19+ lymphocytes (J=0.79) and circulating immune complexes (J=0.73); low – for immunoglobulin E (J=0.42) and CD3+ lymphocytes (J=0.39). CD4+ lymphocytes (J=0.22) and the immunoregulatory index (J=0.06) had no prognostic value. A good effect was predicted by IgG ≥21 g/L, IgA ≥8.1 g/L and IgM ≥1.7 g/L. On the training sample (n=300), the algorithm gave 78% correct, 18% indeterminate and 4% erroneous predictions.
Conclusions. The aim of the study was achieved: an algorithm for predicting the efficacy of therapy in blastocystosis based on immunological parameters was developed; humoral immunity parameters were the most informative. The proportion of erroneous predictions did not exceed the preset 5% level; the algorithm requires validation on an independent sample.
Keywords: infectious and parasitic diseases, Blastocystis infections, immunoglobulins, T-lymphocyte subsets, treatment outcome.
References
Andersen LO, Stensvold CR. Blastocystis in health and disease: are we moving from a clinical to a public health perspective? J Clin Microbiol. 2016;54(3):524-8. DOI: 10.1128/JCM.02520-15. PMID: 26677249.
Aykur M, Malatyalı E, Demirel F, Cömert-Koçak B, Gentekaki E, Tsaousis AD, Dogruman-Al F. Blastocystis: a mysterious member of the gut microbiome. Microorganisms. 2024;12(3):461. DOI: 10.3390/microorganisms12030461. PMID: 38543512.
Esteghamati A, Khanaliha K, Bokharaei-Salim F, Sayyahfar S, Ghaderipour M. Prevalence of intestinal parasitic infection in cancer, organ transplant and primary immunodeficiency patients in Tehran, Iran. Asian Pac J Cancer Prev. 2019;20(2):495-501. DOI: 10.31557/APJCP.2019.20.2.495. PMID: 30803212.
Fontanelli Sulekova L, Gabrielli S, Furzi F, Milardi GL, Biliotti E, De Angelis M, et al. Molecular characterization of Blastocystis subtypes in HIV-positive patients and evaluation of risk factors for colonization. BMC Infect Dis. 2019;19(1):876. DOI: 10.1186/s12879-019-4537-7. PMID: 31640585.
Sarzhanov F, Dogruman-Al F, Santin M, Maloney JG, Gureser AS, Karasartova D, Taylan-Ozkan A. Investigation of neglected protists Blastocystis sp. and Dientamoeba fragilis in immunocompetent and immunodeficient diarrheal patients using both conventional and molecular methods. PLoS Negl Trop Dis. 2021;15(10):e0009779. DOI: 10.1371/journal.pntd.0009779. PMID: 34613993.
Figueiredo AM, Dashti A, Maloney JG, Molokin A, George NS, Köster PC, et al. Blastocystis in free-ranging wild ruminant species across the Iberian Peninsula. Vet Res. 2025;56(1):145. DOI: 10.1186/s13567-025-01563-3. PMID: 40635077.
Zhao W, Ren G, Wang L, Xie L, Wang J, Mao J, et al. Molecular prevalence and subtype distribution of Blastocystis spp. among children who have diarrheia or are asymptomatic in Wenzhou, Zhejiang Province, China. Parasite. 2024;31:12. DOI: 10.1051/parasite/2024012. PMID: 38450718.
El Safadi D, Cian A, Nourrisson C, Pereira B, Morelle C, Bastien P, et al. Prevalence, risk factors for infection and subtype distribution of the intestinal parasite Blastocystis sp. from a large-scale multi-center study in France. BMC Infect Dis. 2016;16(1):451. DOI: 10.1186/s12879-016-1776-8. PMID: 27566417.
Roberts T, Barratt J, Harkness J, Ellis J, Stark D. Comparison of microscopy, culture, and conventional polymerase chain reaction for detection of Blastocystis sp. in clinical stool samples. Am J Trop Med Hyg. 2011;84(2):308-12. DOI: 10.4269/ajtmh.2011.10-0447. PMID: 21292905.
Wang W, Bielefeldt-Ohmann H, Traub RJ, Cuttell L, Owen H. Location and pathogenic potential of Blastocystis in the porcine intestine. PLoS One. 2014;9(8):e103962. DOI: 10.1371/journal.pone.0103962. PMID: 25093578.
Nagel R, Traub RJ, Kwan MM, Bielefeldt-Ohmann H. Blastocystis specific serum immunoglobulin in patients with irritable bowel syndrome (IBS) versus healthy controls. Parasit Vectors. 2015;8:453. DOI: 10.1186/s13071-015-1069-x. PMID: 26373392.
Puthia MK, Lu J, Tan KS. Blastocystis ratti contains cysteine proteases that mediate interleukin-8 response from human intestinal epithelial cells in an NF-kappaB-dependent manner. Eukaryot Cell. 2008;7(3):435-43. DOI: 10.1128/EC.00371-07. PMID: 18156286.
Deng L, Wojciech L, Gascoigne NRJ, Peng G, Tan KSW. New insights into the interactions between Blastocystis, the gut microbiota, and host immunity. PLoS Pathog. 2021;17(2):e1009253. DOI: 10.1371/journal.ppat.1009253. PMID: 33630979.
Rojas-Velázquez L, Morán P, Serrano-Vázquez A, Portillo-Bobadilla T, González E, Pérez-Juárez H, et al. The regulatory function of Blastocystis spp. on the immune inflammatory response in the gut microbiome. Front Cell Infect Microbiol. 2022;12:967724. DOI: 10.3389/fcimb.2022.967724. PMID: 36118018.
Roberts T, Stark D, Harkness J, Ellis J. Update on the pathogenic potential and treatment options for Blastocystis sp. Gut Pathog. 2014;6:17. DOI: 10.1186/1757-4749-6-17. PMID: 24883113.
Bodnia I, Bodnia K, Maslova V, Ogienko V, Pavliy V. Clinical predictors of blastocystosis treatment efficacy. Georgian Med News. 2024;(349):116-9. PMID: 38963214.
Bodnia I, Yurko K, Bodnia K. Relation of the immunologic status of blastocystosis patients with the effectiveness of their therapy. Azerbaijan Medical Journal. 2024;64(5):11353-6. Available at: https://repo.knmu.edu.ua/handle/123456789/35353
Gubler EV. Computational methods of analysis and recognition of pathological processes. USSR: Medicine; 1978. 296 p.
Elhadad H, Abdel-Fattah BM, Saleh SAM, Abo El-Hoda M, El-Taweel H. Assessment of immunological and hematological parameters in Blastocystis species-infected chronic leukemic patients. Gut Pathog. 2025;17(1):58. DOI: 10.1186/s13099-025-00733-0. PMID: 40790503.
Yegit OO, Tuzer C, Yegit OO, Sonmez N, Ertek B, Demirpek U, et al. The eradication of Blastocystis spp. subtype 3 improves the course of chronic spontaneous urticaria. Int Arch Allergy Immunol. 2025;186(12):1142-54. DOI: 10.1159/000545200. PMID: 40068650.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

